D-0023-2022 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0023-2022 was initiated by Teva Pharmaceuticals USA on Sep 22, 2021 and is designated Class II. Reason for recall: Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol The recall status is terminated (terminated Feb 16, 2023). Affected quantity: 1,978 inhalers.

Recall details

Product Type
Drugs
Report Date
Oct 27, 2021
Initiation Date
Sep 22, 2021
Termination Date
Feb 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,978 inhalers

Product description

AirDuo Digihaler 55/14 (fluticasone propionate 55 mcg and salmeterol 14 mcg) Inhalation Powder, Rx Only, Mktd by: Teva Respiratory, LLC Frazer, PA 19355, Manufactured in Ireland, NDC 59310-111-06

Reason for recall

Subpotent drug: OOS results of Label Claimed Emitted Dose for salmeterol

Distribution pattern

USA Nationwide

Code information

AFR16A

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0023-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0023-2022. Report a data issue: hello@regdatalab.com.